RESUMO
Introducción. El cáncer es una de las primeras causas de muerte en nuestra población. Las complicaciones neurológicas asociadas son frecuentes e incrementan significativamente la morbilidad y la mortalidad de estos pacientes. Objetivo. Describir las manifestaciones neurológicas en pacientes con cáncer. Pacientes y métodos. Desde enero de 2010 hasta diciembre de 2014 se creó una base de datos de pacientes con cáncer que merecían una valoración por neurooncología en un centro de referencia. Resultados. Se describen 17.092 motivos de consulta de neurooncología. Las neoplasias que más se relacionaron con manifestaciones neurológicas fueron: cáncer de mama, neoplasias hematológicas, tumores primarios del sistema nervioso central, cáncer de pulmón y neoplasias ginecológicas. Las manifestaciones neurológicas más frecuentes fueron: afección neuromuscular, actividad tumoral en el sistema nervioso central, cefalea primaria, crisis convulsivas, enfermedad vascular cerebral y tumores neurológicos primarios. Conclusiones. Es importante que los neurólogos, médicos de distintas áreas de la medicina y personal paramédico, involucrados en el manejo de estos pacientes, reconozcan las complicaciones neurológicas de manera temprana (AU)
Introduction. Cancer is one of the leading causes of death in our population; neurologic manifestations are frequent and are associated with higher rates of morbidity and mortality. Aim. To describe the neurological manifestations in patients with cancer. Patients and methods. From January 2010 to December 2014 a database was created from patients with cancer, required a neuro-oncological assessment at a referral cancer center. Results. 17,092 reasons for neuro-oncological consultation are described. Neoplasms most frequently associated with neurological manifestations were: breast cancer, hematologic malignancies, primary central nervous system tumors, lung cancer and gynecological malignancies. The most frequent neurological manifestations were: neuromuscular disease (including neuropathy), central nervous system metastasis, primary headaches, seizures, stroke and primary neurological tumors. Conclusion. It is important that neurologists, physicians and those involved in the management of patients with cancer recognize and get to know the neurological complications (AU)
Assuntos
Humanos , Masculino , Feminino , Neoplasias/complicações , Neoplasias/diagnóstico , Neoplasias/mortalidade , Metástase Neoplásica/patologia , Metástase Neoplásica/fisiopatologia , Doenças do Sistema Nervoso/complicações , Doenças do Sistema Nervoso/mortalidade , Exame Neurológico/instrumentação , Exame Neurológico/métodos , Exame Neurológico , Diagnóstico Diferencial , Envelhecimento , Prognóstico , Detecção Precoce de Câncer/instrumentação , Detecção Precoce de Câncer/métodos , Qualidade de Vida , Neurologia/tendências , Institutos de Câncer , Oncologia/instrumentação , Oncologia/métodos , Oncologia/tendências , México/epidemiologiaRESUMO
Glioblastoma multiforme is one of the most aggressive central nervous system tumors and with worse prognosis. Until now,treatments have managed to significantly increase the survival of these patients, depending on age, cognitive status, and autonomy of the individuals themselves. Based on these parameters, both initial or recurrence treatments are performed, as well as monitoring of disease by imaging studies. When the patient enters the terminal phase and curative treatments are suspended, respect for the previous wishes of the patient and development and implementation of palliative therapies must be guaranteed.
